PROJECT 2: STRUCTURAL BASIS OF THE ANTI-ATHEROGENIC PROPERTIES OF APO A-l The goal of this project is to elucidate the molecular mechanisms underlying the functions of apolipoprotein (apo) A-l in reverse cholesterol transport (RCT). ApoA-l is the major protein of plasma highdensity lipoprotein (HDL) and the functions of this molecule underlie the anti-atherogenic properties of the lipoprotein.
Specific Aim 1 is to define the key properties of the two tertiary structure domains of the apoA-l molecule, and to better define lipid-free human apoA-l structure in dilute solution at physiological concentrations. The influence of the properties of the two apoA-l structural domains on the affinity and mechanism of lipid binding will also be investigated. These objectives will be accomplished by using engineered apoA-l molecules and a range of physical-biochemical methods.
Specific Aim 2 is to establish the mechanistic basis for the biogenesis of heterogeneous nascent HDL particles via the ATP-binding cassette transporter Al (ABCA1 )-mediated efflux of cellular lipids to apoA-l. The role of apoA-l structure and influence of cell type will be determined by measuring the efflux of phospholipid and cholesterol molecules from macrophages, fibroblasts and liver cells growing in culture to engineered apoA-l molecules.
Specific Aim 3 is to define the effects of the properties of the tertiary structural domains of apoA-l on the protein's functionality in cholesterol transport using adeno-associated virus-induced expression of natural human apoA-l variants in mice to assess the effects on RCT and atherosclerosis (in collaboration with Project 3). The functionalities of the mouse HDL particles containing the apoA-l mutations in mediating cholesterol transport into and out of cells will be determined in collaboration with Project 1. The incidence of premature coronary artery disease is reduced in human populations with elevated levels of plasma HDL cholesterol and apoA-l. The reasons for this protective effect are not understood fully and this project seeks to uncover the molecular mechanisms underlying the beneficial properties of apoA-l.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Hospital of Philadelphia
United States
Zip Code
Cuchel, Marina; Raper, Anna C; Conlon, Donna M et al. (2017) A novel approach to measuring macrophage-specific reverse cholesterol transport in vivo in humans. J Lipid Res 58:752-762
Lagor, William R; Fields, David W; Bauer, Robert C et al. (2014) Genetic manipulation of the ApoF/Stat2 locus supports an important role for type I interferon signaling in atherosclerosis. Atherosclerosis 233:234-41
Nagao, Kohjiro; Hata, Mami; Tanaka, Kento et al. (2014) The roles of C-terminal helices of human apolipoprotein A-I in formation of high-density lipoprotein particles. Biochim Biophys Acta 1841:80-7
Weibel, Ginny L; Drazul-Schrader, Denise; Shivers, Debra K et al. (2014) Importance of evaluating cell cholesterol influx with efflux in determining the impact of human serum on cholesterol metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 34:17-25
Phillips, Michael C (2014) Molecular mechanisms of cellular cholesterol efflux. J Biol Chem 289:24020-9
Yang, Yanbo; Kuwano, Takashi; Lagor, William R et al. (2014) Lipidomic analyses of female mice lacking hepatic lipase and endothelial lipase indicate selective modulation of plasma lipid species. Lipids 49:505-15
Chetty, Palaniappan Sevugan; Nguyen, David; Nickel, Margaret et al. (2013) Comparison of apoA-I helical structure and stability in discoidal and spherical HDL particles by HX and mass spectrometry. J Lipid Res 54:1589-97
Nguyen, David; Nickel, Margaret; Mizuguchi, Chiharu et al. (2013) Interactions of apolipoprotein A-I with high-density lipoprotein particles. Biochemistry 52:1963-72
Alexander, Eric T; Phillips, Michael C (2013) Influence of apolipoprotein A-I and apolipoprotein A-II availability on nascent HDL heterogeneity. J Lipid Res 54:3464-70
Patel, Parin J; Khera, Amit V; Wilensky, Robert L et al. (2013) Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. Eur J Heart Fail 15:1215-9

Showing the most recent 10 out of 336 publications